Shareholders’ Equity (Details Narrative) - USD ($)							9 Months Ended
	Apr. 05, 2023	Apr. 05, 2023	Apr. 03, 2023	Jul. 15, 2022	Apr. 19, 2022	Apr. 13, 2022	Sep. 30, 2023	Sep. 30, 2022	Jul. 24, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Preferred stock offering								$ 32,453,000
Proceeds from issuance of common stock							$ 13,848,000	$ 32,812,000
Conversion of stock, description							A holder is prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of our common stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership limitation solely as to itself up to 19.99% of the number of shares of our common stock outstanding immediately after giving effect to the conversion, provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect to the issuance of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer apply to the holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval).
Conversion price percentage				140.00%
Net proceeds to immediately redeem
Common stock, shares authorized							230,000,000		230,000,000	230,000,000
Common stock no par value							$ 0			$ 0
Common stock, shares issued							8,260,762			5,932,191
Common stock, shares outstanding							8,260,762			5,932,191
Number of common stock purchase warrants							819,767
Maximum [Member]
Class of Stock [Line Items]
Warrant exercise price per share							$ 109.20
Minimum [Member]
Class of Stock [Line Items]
Warrant exercise price per share							$ 30.60
Over-Allotment Option [Member]
Class of Stock [Line Items]
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares						196,998
Net proceeds					$ 32,800,000
April 2022 Warrants [Member] | Over-Allotment Option [Member]
Class of Stock [Line Items]
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares						1,313,320
April 2022 Warrants [Member] | IPO [Member]
Class of Stock [Line Items]
Number of common stock purchase warrants						1,313,320
Sale of stock, price per share						$ 26.65
Common Stock [Member]
Class of Stock [Line Items]
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares								1,314,000
Preferred stock offering								$ 32,453,000
Net proceeds to immediately redeem
Shares issued price per share						$ 0.20
Common Stock [Member] | IPO [Member]
Class of Stock [Line Items]
Number of common stock purchase warrants						656,660
Shares issued price per share						$ 26.45
Warrant [Member] | IPO [Member]
Class of Stock [Line Items]
Warrant exercise price per share						$ 0.20
Registered Direct Offering [Member]
Class of Stock [Line Items]
Proceeds from issuance of common stock			$ 13,900,000
Registered Direct Offering [Member] | Maximum [Member]
Class of Stock [Line Items]
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares			2,278,121
Registered Direct Offering [Member] | Board Members [Member]
Class of Stock [Line Items]
Shares issued price per share			$ 7.08
Registered Direct Offering [Member] | Board Members [Member] | Maximum [Member]
Class of Stock [Line Items]
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares			2,278,121
Registered Direct Offering [Member] | Other Investors [Member]
Class of Stock [Line Items]
Shares issued price per share			$ 6.03
Underwriting Agreement [Member]
Class of Stock [Line Items]
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares						196,998
Shares issued price per share						$ 24.85
Underwriting Agreement [Member] | April 2022 Warrants [Member]
Class of Stock [Line Items]
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares						196,998
Underwriting Agreement [Member] | Common Stock [Member]
Class of Stock [Line Items]
Number of common stock purchase warrants						98,499
Underwriting Agreement [Member] | Warrant [Member]
Class of Stock [Line Items]
Number of common stock purchase warrants						196,998
Series A Redeemable Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock outstanding percentage						51.00%
Cash in hand						$ 8,000,000
Indebtedness expenses						$ 15,000,000
Dividends rate						6.00%
Temporary equity, shares issued							5,000			6,000
Temporary equity, shares oustanding							5,000			6,000
Series A Redeemable Convertible Preferred Stock [Member] | Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred shares								6,000
Preferred stock offering
Number of stock redeem, shares							(1,000)
Net proceeds to immediately redeem							$ (1,000,000)
Temporary equity, shares issued							4,818			5,882
Temporary equity, shares oustanding							4,818			5,882
Series A Redeemable Convertible Preferred Stock [Member] | Oncocyte Corp [Member] | Preferred Stock [Member]
Class of Stock [Line Items]
Ownership percentage						50.00%
Series A Redeemable Convertible Preferred Stock [Member] | Interest [Member] | Preferred Stock [Member]
Class of Stock [Line Items]
Ownership percentage						51.00%
Series A Redeemable Convertible Preferred Stock [Member] | Security [Member] | Preferred Stock [Member]
Class of Stock [Line Items]
Ownership percentage						50.00%
Series A Redeemable Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares						11,765
Convertible preferred shares						384,477
Conversion price						$ 30.60
Preferred stock offering						$ 850
Stated value per share						$ 1,000
Gross proceeds, closing						$ 10,000,000
Proceeds from issuance of common stock						4,900,000
Series A Redeemable Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Class of Stock [Line Items]
Preferred stock offering						$ 5,000,000
Series A Redeemable Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member] | Investors [Member]
Class of Stock [Line Items]
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares						11,765
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred shares	588.23529
Preferred stock, dividend rate, percentage							6.00%
Dividends, preferred stock							$ 399,000
Series A Preferred Stock [Member] | Oncocyte Corp [Member]
Class of Stock [Line Items]
Equity method investment, description of principal activities							if the daily volume weighted average price of our common stock for 20 out of 30 trading days exceeds 140% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or exceeds 20,000 shares of our common stock
Series A Preferred Stock [Member] | Registered Direct Offering [Member]
Class of Stock [Line Items]
Number of stock redeem, shares		1,064
Net proceeds to immediately redeem		$ 1,100,000
Common Stock [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares			2,274,709
Series B Preferred Stock [Member] | Registered Direct Offering [Member]
Class of Stock [Line Items]
Number of stock redeem, shares			1,064
Net proceeds to immediately redeem			$ 1,100,000